Dr. Jamie McDonald is a Senior Clinical MS/Neuroimmunology Fellow at Stanford MS Center. She is a National MS Society Sylvia Lawry Fellow for 2020-2022. Dr. McDonald completed her undergraduate degree at Cornell University followed by Master of Science in Human Nutrition at Columbia University Institute of Human Nutrition. She earned her medical degree from the Royal College of Surgeons in Ireland. As part of her fellowship, she is pursuing a masters degree in epidemiology and clinical research.

Professional Education

  • Master of Science, Stanford University, EPIDM-MS (2022)
  • Bachelor of Science, Cornell University (2007)
  • B of Medicine and B of Surgery, Royal College Of Surgeons (2021)
  • Fellowship, Stanford University, MS/Neuroimmunology
  • Neurology Residency, University of Utah, Adult Neurology (2020)
  • Internship, University of Utah, Internal Medicine (2017)
  • MD, Royal College of Surgeons in Ireland, Graduate Entry Medicine (2016)
  • MS, Columbia University, Human Nutrition (2012)
  • BS, Cornell University, Human Development (2007)

Current Clinical Interests

  • Multiple Sclerosis
  • Neuromyelitis Optica
  • Autoimmune encephalitis
  • Myelin Oligodendrocyte Glycoprotein Antibody Disease
  • Stiff Person Syndrome Spectrum Disorder

All Publications

  • Dietary factors and pediatric multiple sclerosis: A case-control study MULTIPLE SCLEROSIS JOURNAL Pakpoor, J., Seminatore, B., Graves, J. S., Schreiner, T., Waldman, A. T., Lotze, T. E., Belman, A., Greenberg, B. M., Weinstock-Guttman, B., Aaen, G., Tillema, J., McDonald, J. C., Hart, J., Ness, J. M., Harris, Y., Rubin, J., Candee, M., Krupp, L., Gorman, M., Benson, L., Rodriguez, M., Chitnis, T., Mar, S., Kahn, I., Rose, J., Carmichael, S. L., Roalstad, S., Waltz, M., Casper, T., Waubant, E., US Network Pediat Multiple Scleros 2018; 24 (8): 1067–76


    The role of diet in multiple sclerosis (MS) is largely uncharacterized, particularly as it pertains to pediatric-onset disease.To determine the association between dietary factors and MS in children.Pediatric MS patients and controls were recruited from 16 US centers (MS or clinically isolated syndrome onset before age 18, <4 years from symptom onset and at least 2 silent lesions on magnetic resonance imaging). The validated Block Kids Food Screener questionnaire was administered 2011-2016. Chi-squared test compared categorical variables, Kruskal-Wallis test compared continuous variables, and multivariable logistic regression analysis was performed.In total, 312 cases and 456 controls were included (mean ages 15.1 and 14.4 years). In unadjusted analyses, there was no difference in intake of fats, proteins, carbohydrates, sugars, fruits, or vegetables. Dietary iron was lower in cases ( p = 0.04), and cases were more likely to consume below recommended guidelines of iron (77.2% of cases vs 62.9% of controls, p < 0.001). In multivariable analysis, iron consumption below recommended guidelines was associated with MS (odds ratio = 1.80, p < 0.01).Pediatric MS cases may be less likely to consume sufficient iron compared to controls, and this warrants broader study to characterize a temporal relationship. No other significant difference in intake of most dietary factors was found.

    View details for PubMedID 28608728

    View details for PubMedCentralID PMC5711616

  • Effect of medication and STN-DBS on postural control in subjects with Parkinson's disease PARKINSONISM & RELATED DISORDERS Nantel, J., McDonald, J. C., Bronte-Stewart, H. 2012; 18 (3): 285-289


    To assess the effect of disease severity, dopaminergic medication (med) and STN-DBS on postural stability in Parkinson's disease (PD).Postural sway in quiet stance, and the Unified Parkinson's Disease Rating Scale (motor) (UPDRS III) were evaluated in 129 subjects in the off-med state. A subgroup of 28 subjects was studied on-med and after STN-DBS. Postural sway was measured using center of pressure (CoP) root mean square displacement (RMS(CoP)) and mean velocity (V(CoP)) in the anterior-posterior (AP) and medial-lateral (ML) directions.All CoP parameters were larger in moderate/advanced subjects vs controls (P < 0.001) and early subjects. Only RMS(CoP)ML was larger in early subjects vs controls (P < 0.05). Med, DBS and DBS + med decreased UPDRS III compared to off-med (P < 0.001). RMS(CoP)ML and V(CoP)ML were larger on-med vs off-med and vs DBS (P < 0.001). Compared to controls and PD subjects with normal CoP sway off-med, med increased all CoP parameters (P < 0.01) but DBS returned V(CoP)ML to normal values. For 'abnormal' PD subjects, STN-DBS improved the excessive V(CoP) in ML compared to off and on-med pre-DBS (P < 0.05).Postural sway in quiet stance increased with disease severity. Only ML CoP displacement was abnormal in early stage PD, and this may be a compensatory mechanism. Medication increased ML postural sway. In 'normal' PD subjects, STN-DBS reversed medication induced postural instability. Subjects with abnormal balance in quiet stance did not benefit from medication or DBS, except for improvement in ML CoP velocity from DBS. This may serve to reduce postural instability and falling.

    View details for DOI 10.1016/j.parkreldis.2011.11.005

    View details for Web of Science ID 000301813200015

    View details for PubMedID 22130147